Literature DB >> 34731030

Unlocking the Code to Management of Neuroendocrine Neoplasms: A Clinician's Perspective.

Paul D Ehrlichman1, Namrata Vijayvergia1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34731030      PMCID： PMC9014463          DOI： 10.1200/OP.21.00628

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN： 2688-1527


× No keyword cloud information.
  13 in total

1.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

Review 2.  PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

Authors:  Halfdan Sorbye; Grace Kong; Simona Grozinsky-Glasberg
Journal:  Endocr Relat Cancer       Date:  2020-03       Impact factor: 5.678

3.  177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

Authors:  Jonathan R Strosberg; Martyn E Caplin; Pamela L Kunz; Philippe B Ruszniewski; Lisa Bodei; Andrew Hendifar; Erik Mittra; Edward M Wolin; James C Yao; Marianne E Pavel; Enrique Grande; Eric Van Cutsem; Ettore Seregni; Hugo Duarte; Germo Gericke; Amy Bartalotta; Maurizio F Mariani; Arnaud Demange; Sakir Mutevelic; Eric P Krenning
Journal:  Lancet Oncol       Date:  2021-11-15       Impact factor: 41.316

Review 4.  Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors.

Authors:  Janie Y Zhang; Pamela L Kunz
Journal:  JCO Oncol Pract       Date:  2021-10-15

5.  Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.

Authors:  Juan M Sarmiento; Glenroy Heywood; Joseph Rubin; Duane M Ilstrup; David M Nagorney; Florencia G Que
Journal:  J Am Coll Surg       Date:  2003-07       Impact factor: 6.113

6.  Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.

Authors:  Camilla B Johnbeck; Ulrich Knigge; Annika Loft; Anne K Berthelsen; Jann Mortensen; Peter Oturai; Seppo W Langer; Dennis R Elema; Andreas Kjaer
Journal:  J Nucl Med       Date:  2016-09-22       Impact factor: 10.057

7.  Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.

Authors:  Eran Sadot; Diane L Reidy-Lagunes; Laura H Tang; Richard Kinh Gian Do; Mithat Gonen; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Bas Groot Koerkamp; Brian R Untch; Murray F Brennan; William R Jarnagin; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2015-11-23       Impact factor: 5.344

8.  Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?

Authors:  Elettra Merola; Wouter Zandee; Louis de Mestier; Heinz Josef Klümpen; Karolina Makulik; Karen Geboes; Marie Louise van Velthuysen; Anne Couvelard; Jérôme Cros; Susanne van Eeden; Anne Hoorens; Timothy Stephenson; W Zajęcki; Wouter de Herder; Alia Munir
Journal:  Neuroendocrinology       Date:  2020-03-11       Impact factor: 4.914

Review 9.  Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.

Authors:  Vincenzo Marotta; Maria Chiara Zatelli; Concetta Sciammarella; Maria Rosaria Ambrosio; Marta Bondanelli; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocr Relat Cancer       Date:  2017-10-24       Impact factor: 5.678

10.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.